First, mTOR inhibitors or PI3K/mTOR inhibitors, such as sirolimus (rapamycin) and omipalisib (GSK2126458), have completed randomized, double-blind phase I clinical trials for patients with IPF. Here, MTOR is linked to idiopathic pulmonary fibrosis.